DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome.
about
Haemolytic uraemic syndrome.Novel developments in thrombotic microangiopathies: is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura?Membrano-proliferative glomerulonephritis, atypical hemolytic uremic syndrome, and a new complement factor H mutation: report of a case.Does early initiation of therapeutic plasma exchange improve outcome in pediatric stem cell transplant-associated thrombotic microangiopathy?Anti-glomerular basement membrane glomerulonephritis and thrombotic microangiopathy in first degree relatives: a case report.Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndromeAbnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathySuccessful treatment of DEAP-HUS with eculizumab.Autoimmune polyglandular syndrome type 3c with ectodermal dysplasia, immune deficiency and hemolytic-uremic syndromeAtypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literatureOveractivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement.Favorable four-yr outcome after renal transplantation in a patient with complement factor H antibody and CFHR1/CFHR3 gene mutation-associated HUS.Indications of underdiagnosis of atypical haemolytic uraemic syndrome in a cohort referred to the Coagulation Unit in Malmo, Sweden, for analysis of ADAMTS13 2007-2012.Anti-complement-factor H-associated glomerulopathies.New insights into disease-specific absence of complement factor H related protein C in mouse models of spontaneous autoimmune diseasesGenetics of age-related macular degeneration: current concepts, future directions.Causes of alternative pathway dysregulation in dense deposit disease.Oxidative stress, innate immunity, and age-related macular degenerationThe Genetics of Ultra-Rare Renal Disease.Adjustment of Eculizumab Dosage Pattern in Patients with Atypical Hemolytic Uremic Syndrome with Suboptimal Response to Standard Treatment Pattern.Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology.At the Cross Section of Thrombotic Microangiopathy and Atypical Hemolytic Uremic Syndrome: A Narrative Review of Differential Diagnostics and a Problematization of Nomenclature.Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS.Streptococcus pneumoniae From Patients With Hemolytic Uremic Syndrome Binds Human Plasminogen via the Surface Protein PspC and Uses Plasmin to Damage Human Endothelial Cells.Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab.Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.
P2860
Q30244707-07BF18EC-BC8A-4055-B76A-05B2DEA11ACCQ33395774-132C04BA-BD34-4C16-AC32-8C3B22ABC288Q33401621-43F81559-6B95-4AE9-920F-4BEEF8877DBFQ33402385-44CFA9FB-2DAB-464A-96B3-5881C9340EDCQ33402542-0730B739-791D-4D69-9594-FFF8315E84D4Q33402827-16FC4CD8-3EE1-4950-AA13-017AE1170B91Q33408788-E4229E8A-7DC1-431D-9B70-ACB02343A32FQ33411577-07D24F6E-4A04-4E5F-89E1-32693547907CQ33414000-09F7C2B4-9F30-4BBD-B884-96BAC8E838F2Q33419812-BA732FED-7DD6-407A-9FAA-383BDA341BAFQ33423118-DC42D190-DD38-478E-A586-06ADBFF4DCE0Q33423743-49B66034-FD31-4AF5-AEEE-B9D676D0EB00Q33432215-6DBFCF30-4BFB-492A-A002-07109464E433Q33434103-5BE6E3F9-9E34-46E4-8A76-103653CB6A03Q34146380-AF5CA901-3CBF-4729-922C-406DCF5C736AQ34565573-6DB9F7F6-D8BD-4AB9-BD52-EA7B21B2C614Q35758595-778584A8-D98A-4ADA-95FA-D102B9E81CEBQ36940296-C03FC923-D0DF-4E6A-8872-4ED185D86C0BQ37032691-4A6A0256-56B6-4DB6-AD61-677CF23E5CFEQ37497101-05CC6B06-B8FA-4C58-9BCD-690089A04DC0Q39200048-F96C79C9-EBC6-4B2C-B296-DA6FA85431F4Q39309248-545D7B5A-B30B-42A2-A120-9BD8ED903568Q40324683-728D5ECF-590B-4906-86FF-44512CEFACE0Q47714965-7124776B-06D2-450B-B62F-5E7D21BA7DD8Q51333222-40A7183E-C1E7-443D-A68A-5B9190D9656CQ51568998-22A02E60-204C-40F0-902A-9FBB213D4B09
P2860
DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
DEAP-HUS: deficiency of CFHR p ...... of hemolytic uremic syndrome.
@ast
DEAP-HUS: deficiency of CFHR p ...... of hemolytic uremic syndrome.
@en
type
label
DEAP-HUS: deficiency of CFHR p ...... of hemolytic uremic syndrome.
@ast
DEAP-HUS: deficiency of CFHR p ...... of hemolytic uremic syndrome.
@en
prefLabel
DEAP-HUS: deficiency of CFHR p ...... of hemolytic uremic syndrome.
@ast
DEAP-HUS: deficiency of CFHR p ...... of hemolytic uremic syndrome.
@en
P2093
P2860
P1433
P1476
DEAP-HUS: deficiency of CFHR p ...... of hemolytic uremic syndrome.
@en
P2093
Christine Skerka
Christoph Licht
Christoph Mache
Dominik Müller
European DEAP-HUS Study Group
Marianne Wigger
P2860
P2888
P304
P356
10.1007/S00467-010-1446-9
P577
2010-02-16T00:00:00Z
P6179
1003986446